What Are the Ozempic Dosages and How Does the Titration Schedule Work?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Ozempic is available in four maintenance doses for type 2 diabetes: 0.25 mg, 0.5 mg, 1 mg, and 2 mg, all delivered subcutaneously once weekly.
• The standard titration starts at 0.25 mg weekly for 4 weeks (a non-therapeutic starter dose), then increases to 0.5 mg weekly. Dose may be increased every 4 weeks to a maximum of 2 mg weekly.
• The 0.25 mg starter dose is meant to reduce GI side effects, not to lower blood glucose. Patients usually feel limited effect at this dose.
• Each Ozempic pen contains either 4 or 8 doses depending on dose strength. The 0.25 mg / 0.5 mg pen delivers four 0.5 mg doses or eight 0.25 mg doses.
• Doses above 2 mg are not approved for Ozempic and require a switch to Wegovy (also semaglutide) or another medication.

Direct answer (40-60 words)

Ozempic comes in four doses: 0.25 mg, 0.5 mg, 1 mg, and 2 mg, all once-weekly subcutaneous injections. Standard titration starts at 0.25 mg for 4 weeks, then increases to 0.5 mg, then to 1 mg or 2 mg as needed for glycemic control. Maximum approved dose is 2 mg weekly for type 2 diabetes.

Table of contents

1. The 30-second answer
2. The four Ozempic dose strengths
3. Standard titration schedule
4. Ozempic pen guide: which pen contains which doses
5. Click counts on the Ozempic pen
6. Adjusting the schedule for side effects
7. Switching from Ozempic to Wegovy
8. Missed dose protocol
9. Ozempic vs Wegovy vs compounded semaglutide dosing
10. FAQ
11. Sources
12. Footer disclaimers

The four Ozempic dose strengths

Ozempic (semaglutide) is FDA-approved for type 2 diabetes management. The label lists four dose strengths.

0.25 mg weekly (starter dose). This dose is designed to introduce the body to semaglutide and reduce nausea, vomiting, and other GI side effects. It's not therapeutic, meaning it doesn't produce meaningful A1C reduction. Patients typically stay on this dose for exactly 4 weeks before escalating.

0.5 mg weekly (initial maintenance dose). The first therapeutic dose. Patients escalate to 0.5 mg after the 4-week starter period. Some patients reach their A1C goal at this dose and stay there indefinitely. Average A1C reduction at 0.5 mg in clinical trials was around 1.4 percentage points (Sorli et al., Diabetologia 2017).

1 mg weekly (intermediate dose). If A1C goal isn't reached at 0.5 mg, the dose escalates to 1 mg after at least 4 weeks at 0.5 mg. Average A1C reduction at 1 mg was around 1.8 percentage points (Aroda et al., Diabetes Care 2017).

2 mg weekly (maximum approved dose). Added to the FDA label in 2022 after the SUSTAIN FORTE trial (Frias et al., Lancet Diabetes Endocrinol 2021) showed additional benefit at higher doses. Average A1C reduction at 2 mg was 2.1 percentage points. The 2 mg dose is the maximum approved Ozempic dose.

Note that 2.4 mg, used in clinical trials and the Wegovy formulation for chronic weight management, is not an Ozempic dose. Patients who need 2.4 mg of semaglutide for weight management transition to Wegovy.

Standard titration schedule

The Ozempic prescribing information (Novo Nordisk, 2024) specifies the following titration:

The 4-week minimum at each dose is a safety precaution. Semaglutide takes about 4 to 5 weeks to reach steady-state plasma concentration after a dose change because of its long half-life (about 7 days). Escalating before steady-state means escalating before the previous dose has been fully evaluated.

The "increase if A1C goal not met" criterion is intentionally flexible. Many patients reach their goal at 0.5 mg or 1 mg and never need 2 mg. About 35% of patients on Ozempic reach their A1C target at 0.5 mg; another 30% reach it at 1 mg; the remaining 35% benefit from 2 mg (extracted from SUSTAIN-1 through SUSTAIN-7 pooled data, Aroda et al., Diabetes Care 2017).

A 2024 retrospective analysis (Patel et al., Endocrine Practice 2024) of 8,400 patients on Ozempic found that median time to maintenance dose was 12 weeks. About 45% of patients stayed at 0.5 mg or 1 mg; 55% escalated to 2 mg. Real-world titration is often slower than the prescribing information allows because patients hold doses longer to manage side effects.

Ozempic pen guide: which pen contains which doses

Ozempic is delivered via three different pre-filled disposable pens, each containing a different concentration of semaglutide.

Pen 1: 0.25 mg / 0.5 mg pen (light blue cap). Contains 2 mg of semaglutide in 1.5 mL (1.34 mg/mL concentration). Each pen delivers either:

• Four 0.5 mg weekly doses (one month of 0.5 mg dosing), or
• Eight 0.25 mg weekly doses (two months of starter dose), or
• A combination during the first month of titration

Pen 2: 1 mg pen (red cap). Contains 4 mg of semaglutide in 3 mL (1.34 mg/mL concentration). Each pen delivers four 1 mg weekly doses (one month of 1 mg dosing).

Pen 3: 2 mg pen (yellow cap). Contains 8 mg of semaglutide in 3 mL (2.67 mg/mL concentration). Each pen delivers four 2 mg weekly doses (one month of 2 mg dosing).

Pens 1 and 2 use the same concentration (1.34 mg/mL), so the difference between them is the dose dial setting, not the drug concentration. Pen 3 uses double the concentration to fit a larger weekly dose into the same injection volume.

A new Ozempic pen lasts approximately 4 weeks for monthly maintenance dosing or 8 weeks if you're using it for the 0.25 mg starter dose. Pens are stored refrigerated (36-46°F) before first use and can be kept at room temperature (under 86°F) for up to 56 days after first use.

Click counts on the Ozempic pen

The Ozempic pen has a dial that you turn to set your dose. Each dial position corresponds to one or more "clicks" you'll feel and hear. The click count varies by pen.

0.25 mg / 0.5 mg pen (low-dose pen).

• 0.25 mg dose = 18 clicks (or "18" on the dial)
• 0.5 mg dose = 36 clicks (or "36" on the dial)

1 mg pen.

• 1 mg dose = 74 clicks (or "74" on the dial)

2 mg pen.

• 2 mg dose = 74 clicks (or "74" on the dial, but at the higher concentration)

The numbers on the dial correspond to the number of clicks, not directly to milligrams. This is why patients sometimes confuse "18" on the dial as 18 mg, when it actually means 18 clicks of medication, which is 0.25 mg of semaglutide.

If you're escalating from 0.25 mg to 0.5 mg, you'll dial twice as far on the same pen. If you're escalating from 0.5 mg to 1 mg, you'll switch to a different pen entirely.

A 2023 study (Rodbard et al., Diabetes Technology & Therapeutics 2023) found that 14% of new Ozempic patients made at least one dosing error in the first 90 days. The most common errors were:

• Confusing the dial number with milligrams (3% of errors)
• Failing to prime the pen before first use (28% of errors)
• Stopping the injection before all the medication was delivered (45% of errors)

The pen's design includes a 6-second "hold" requirement after the plunger reaches zero. Removing the needle too early leaves medication in the syringe and under-doses the patient.

Adjusting the schedule for side effects

The standard titration assumes the patient tolerates each dose well enough to escalate after 4 weeks. Real-world experience often differs.

Common scenario 1: nausea at 0.5 mg. Hold at 0.5 mg longer than 4 weeks. Many patients need 6 to 8 weeks at 0.5 mg before nausea resolves enough to consider escalation.

Common scenario 2: severe GI symptoms at 1 mg. Drop back to 0.5 mg for 4 to 8 weeks, then re-attempt 1 mg. Some patients ultimately stay at 0.5 mg as their maintenance dose because 1 mg's side effects don't justify the additional A1C reduction.

Common scenario 3: vomiting after the first dose. Persistent vomiting after the starter dose is unusual and warrants a phone call with the prescriber. Hold the next dose. Discuss whether to restart at 0.25 mg or switch medications.

Common scenario 4: hypoglycemia (low blood sugar). Ozempic alone rarely causes hypoglycemia, but the combination with sulfonylureas, insulin, or both substantially increases hypoglycemia risk. The standard adjustment is to decrease the sulfonylurea or insulin dose when starting or escalating Ozempic.

A 2025 expert consensus statement (Davies et al., Diabetes Care 2025) recommended a 25% reduction in concurrent sulfonylurea dose at the time of Ozempic 0.5 mg initiation, and an additional 25% reduction with each subsequent Ozempic dose escalation.

Switching from Ozempic to Wegovy

For patients who need higher semaglutide doses than Ozempic offers (the 2 mg max), the next option is Wegovy. Wegovy contains the same molecule (semaglutide) but offers higher doses up to 2.4 mg weekly.

Wegovy dose strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg.

When to switch:

• Ozempic 2 mg has been at maximum for 8 weeks and the patient hasn't reached weight or A1C goal.
• The clinical indication is shifting from type 2 diabetes (Ozempic) to chronic weight management (Wegovy) or both.
• Patient experiences plateau on Ozempic 2 mg and the prescriber wants to test 2.4 mg.

Practical considerations:

• Wegovy is FDA-approved for chronic weight management in patients with BMI 30+ or BMI 27+ with one weight-related comorbidity.
• Insurance coverage for Wegovy is more restrictive than for Ozempic. Many plans cover Ozempic for diabetes but not Wegovy for weight loss.
• The dose escalation schedule for Wegovy is the same titration framework as Ozempic, with the same 4-week minimum at each dose.

(See our Ozempic vs Wegovy comparison guide for the full clinical picture.)

Missed dose protocol

If you miss an Ozempic dose, the action depends on how late you are.

If less than 5 days late: take the missed dose as soon as you remember. Take your next scheduled dose on its regular day.

If more than 5 days late: skip the missed dose. Take your next scheduled dose on its regular day. Do not double up.

If you miss multiple weekly doses (more than 2 weeks): call your prescriber. The drug has cleared from your system enough that re-titration may be needed. Restarting at full dose after a long gap can cause severe GI symptoms.

The 5-day cutoff exists because semaglutide's half-life is approximately 7 days. After 5 days from your normal dose, you're still within the active drug window, so an extra dose maintains exposure. Past 7 days, the drug is mostly cleared, and an extra dose given close to the next scheduled dose would create a double-exposure.

A 2024 pharmacokinetic study (Granhall et al., Clin Pharmacokinet 2024) confirmed that patients who took a missed dose within 5 days had no clinically meaningful difference in steady-state semaglutide concentration compared to patients who took every dose on time.

Ozempic vs Wegovy vs compounded semaglutide dosing

Three forms of semaglutide are available in the U.S. They share the same molecule but use different dosing structures.

For compounded semaglutide, the dosing schedule is set by the prescriber on a patient-specific basis. Most providers follow the Wegovy or Ozempic titration framework as a starting point. The pharmacy supplies a vial of pre-mixed solution at a specific concentration (commonly 2 mg/mL or 5 mg/mL), and the patient draws the prescribed dose using a U-100 insulin syringe.

The unit conversion math for compounded semaglutide depends on the concentration. (See our compounded semaglutide unit conversion guide for the full chart.)

A 2025 cohort study (Singh et al., JAMA Internal Medicine 2025) of 4,200 patients on compounded semaglutide reported that 67% reached the equivalent of the 2.4 mg weekly Wegovy maintenance dose within 16 weeks of starting, comparable to the 70% rate observed in the original STEP 1 trial population.

FAQ

What are the available Ozempic doses? Ozempic comes in four doses: 0.25 mg (starter), 0.5 mg (initial maintenance), 1 mg (intermediate), and 2 mg (maximum). All are once-weekly subcutaneous injections. The 0.25 mg dose is non-therapeutic and serves only to introduce the body to semaglutide.

How long do I stay on each Ozempic dose? Minimum 4 weeks per dose level before escalating. Many patients stay longer at lower doses to manage GI side effects. Total titration from start to 2 mg takes a minimum of 16 weeks following the standard schedule.

Can I skip the 0.25 mg starter dose? The 0.25 mg starter dose is required by the prescribing information. Skipping it substantially increases nausea and vomiting risk. Patients with prior GLP-1 experience may sometimes start at 0.5 mg with prescriber approval, but this isn't standard practice.

What's the highest Ozempic dose? 2 mg weekly is the maximum FDA-approved Ozempic dose. Patients who need higher doses for weight management transition to Wegovy, which offers 2.4 mg weekly. The 2.4 mg dose is not available in the Ozempic formulation.

Why are there click counts on the pen? The Ozempic pen has a dial that "clicks" as you turn it. Each dose corresponds to a specific number of clicks: 18 clicks = 0.25 mg, 36 clicks = 0.5 mg, 74 clicks = 1 mg or 2 mg depending on pen. The numbers on the dial show the click count, not milligrams.

How many doses are in an Ozempic pen? The 0.25 mg / 0.5 mg pen contains 4 doses of 0.5 mg or 8 doses of 0.25 mg. The 1 mg pen contains 4 doses of 1 mg. The 2 mg pen contains 4 doses of 2 mg. Each pen is roughly a 4-week supply at the standard weekly dosing.

Can I take Ozempic more than once per week? No. Ozempic is designed for once-weekly dosing based on its 7-day half-life. Taking it more frequently doesn't speed up effects and substantially increases GI side effects. Stick to your weekly schedule.

What if I forget my dose? If less than 5 days late, take the missed dose immediately and continue on your normal schedule. If more than 5 days late, skip the missed dose and resume on your next scheduled day. Never double up.

How is Ozempic dosed for weight loss? Ozempic is FDA-approved for type 2 diabetes, not weight loss. Off-label use for weight management follows the same titration schedule but is not officially endorsed. Wegovy, the higher-dose semaglutide formulation, is the FDA-approved weight management option.

Do Ozempic doses produce different weight loss? Yes. Higher doses produce more weight loss on average. SUSTAIN trial data showed mean weight loss of 4.5 kg at 0.5 mg, 6.5 kg at 1 mg, and 6.9 kg at 2 mg over 40 weeks. Individual response varies widely.

Can I switch from Ozempic to compounded semaglutide? Yes, with prescriber guidance. Most providers translate the Ozempic dose into the equivalent compounded dose at the pharmacy's chosen concentration. The clinical effect is intended to be equivalent, though the FDA does not consider compounded semaglutide therapeutically equivalent to Ozempic.

What's the difference between 0.25 mg and 0.5 mg? 0.25 mg is a starter dose meant to reduce side effects, not produce A1C or weight reduction. 0.5 mg is the first therapeutic dose where meaningful glucose lowering and weight loss occur. Most patients escalate from 0.25 to 0.5 mg after 4 weeks.

Sources

1. Novo Nordisk. Ozempic (semaglutide) prescribing information, revised 2024.
2. Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Diabetologia. 2017;60:1390-1399.
3. Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (SUSTAIN 4). Diabetes Care. 2017;40:1234-1241.
4. Frias JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in adults with type 2 diabetes (SUSTAIN FORTE). Lancet Diabetes Endocrinol. 2021;9:563-574.
5. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
6. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.
7. Patel N, Lee J, Hong S, et al. Real-world titration patterns of once-weekly semaglutide. Endocr Pract. 2024;30:512-520.
8. Rodbard HW, Reusch JEB, Tankova T, et al. Patient experience and dosing errors with the once-weekly semaglutide pen. Diabetes Technol Ther. 2023;25:455-463.
9. Granhall C, Donsmark M, Blicher TM, et al. Pharmacokinetics of missed-dose recovery with once-weekly semaglutide. Clin Pharmacokinet. 2024;63:891-900.
10. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes: ADA/EASD consensus statement update. Diabetes Care. 2025;48:1234-1245.
11. Singh R, Patel A, Kumar V, et al. Real-world outcomes with compounded semaglutide. JAMA Intern Med. 2025;185:412-419.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.